CLAIMS

We claim:

1. A compound of Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof:

wherein:

D is C-R and X is N, or

D is N and X is C-R, or

D is C-R and X is C-R,

where each R is independently selected from hydrogen, halo, cyano, or C_1-C_6 alkyl;

R^1 is a group defined by $-(Q)_m-(Q^1)_n-(Q^2)_p$, wherein;

Q is arylene or heteroarylene, and m is 0 or 1,

Q^1 is $O(CH_2)_q$, $(CH_2)_r$ C(O), or $S(O)_2$, and

n is 0 or 1,

q is 0, 1, 2, 3, or 4, and

r is 1, 2, 3, or 4,

Q^2 is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, -OH, C_1-C_3 alkoxy, NR^6R^7, aryl, aryloxy, heteroaryl, heterocyclyl, or R^9R^{10}, and p is 0 or 1

R^2 is –H, or C_1-C_6 alkyl; or

R^1 and R^2 together with the nitrogen to which they are attached form a ring system, said ring system being a substituted or unsubstituted heterocyclyl or heterocyclic spiro ring system;

R^3 is –H or C_1-C_3 alkyl;

R^4 is –H or C_1-C_3 alkyl;

R^5 is –H, halo, -CN, -OH, C_1-C_3 alkyl, C_1-C_3alkoxy, -NO_2, aryl, or NR'R";

R^6 is –H or C_1-C_6 alkyl;

R^7 is –H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, -R^9R^{10}, aralkyl, heterocyclyl, or -C(O)R^8;

R^8 is hydrogen or C_1-C_6 alkyl;

R^9 is C_1-C_6 alkylene or heterocyclylene;

R^{10} is C_1-C_6 alkoxy, aryl, aralkyl, heteroaryl, aryloxy, heterocyclyl, -C(O)OR^8, -C(O)R^8, or -C(O)NR'R";

R' is –H or C_1-C_6 alkyl;

R" is –H, C_1-C_6 alkyl, -C(O)R"', -$S(O)_2$R"', or C(O)NHR"'; and

R"' is C_1-C_6 alkyl, aryl, aralkyl, heteroaryl, or heterocyclyl.

2. A compound as claimed in claim 1, wherein D is N.

3. A compound as claimed in claim 1, wherein D is C–R and R is H.

4. A compound as claimed in claim 1, wherein X is N.

5. A compound as claimed in claim 1, wherein X is C-R and R is H.

6. A compound as claimed in claim 1, wherein D is N, X is C-R, and R is H.

7. A compound as claimed in claim 1, wherein D is C–R, R is H, and X is N.

8. A compound as claimed in claim 1, wherein X is C-R, D is C-R, and each R is H.

9. A compound as claimed in claim 1, wherein m and n are 0, p is 1 and R^1 is $-(Q^2)$.

10. A compound as claimed in claim 1, wherein m and p are 1, n is 0 and R^1 is $-(Q)-(Q^2)$.

11. A compound as claimed in claim 1, wherein m, n, and p are 1, and R^1 is $-(Q)-(Q^1)-(Q^2)$.

12. A compound as claimed in claim 1, wherein m and p are 1 and Q is arylene.

13. A compound as claimed in claim 1, wherein m and p are 1 and Q is heteroarylene.

14. A compound as claimed in claim 1, wherein n and p are 1 and Q^1 is $O(CH_2)_q$, where q is 0, 1, 2, 3, or 4.

15. A compound as claimed in claim 1, wherein n and p are 1 and Q^1 is $(CH_2)_r$ and where r is 1, 2, 3, or 4.

16. A compound as claimed in claim 1, wherein n and p are 1 and Q^1 is C(O).

17. A compound aas claimed in claim 1, wherein n and p are 1 and Q^1 is $S(O)_2$.

18. A compound as claimed in claim 1, wherein p is 1 and Q^2 is NR^6R^7.

19. A compound as claimed in claim 1, wherein p is 1 and Q^2 is heteroaryl.

20. A compound as claimed in claim 1, wherein p is 1 and Q^2 is aryl.

21. A compound as claimed in claim 1, wherein p is 1 and Q^2 is R^9R^{10}.

22. A compound as claimed in claim 1, wherein R^2 is C_1-C_6 alkyl.

23. A compound as claimed in claim 1, wherein R^2 is methyl.

24. A compound as claimed in claim 1, wherein R^2 is -H.

25. A compound as claimed in claim 1, wherein R^3 is C_1-C_6 alkyl.

26. A compound as claimed in claim 1, wherein R^3 is methyl.

27. A compound as claimed in claim 1, wherein R^3 is -H.

28. A compound as claimed in claim 1, wherein R^4 is C_1-C_6 alkyl.

29. A compound as claimed in claim 1, wherein R^4 is methyl.

30. A compound as claimed in claim 1, wherein R^4 is -H.

31. A compound as claimed in claim 1, wherein R^5 is –H, C_1-C_3 alkyl, C_1-C_3 alkoxy, or halo.

32. A compound as claimed in claim 1, wherein R^5 is -H.

33. A compound as claimed in claim 1, wherein R^6 is –H or C_1-C_6 alkyl.

34. A compound as claimed in claim 1, wherein R^6 is -H.

35. A compound as claimed in claim 1, wherein R^7 is C_1-C_6 alkyl.

36. A compound as claimed in claim 1, wherein R^7 is methyl, ethyl or isopropyl.

37. A compound as claimed in claim 1, wherein R^7 is aralkyl.

38. A compound as claimed in claim 1, wherein R^7 is benzyl.

39. A compound as claimed in claim 1, wherein R^7 is R^9R^{10}.

40. A compound as claimed in claim 1, selected from the group consisting of:

(2*E*)-*N*-(1,3-benzothiazol-6-yl)-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-*N*-(3,4-dimethyl-5-isoxazolyl)-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-*N*-(2-cyanophenyl)-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-3-(1*H*-indazol-3-yl)-*N*-(6-methoxy-3-pyridinyl)-2-propenamide;

(2*E*)-*N*-(3-chlorophenyl)-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-*N*-(2,3-dihydro-1*H*-inden-5-yl)-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-*N*-[4-(dimethylamino)phenyl]-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-*N*-(3-cyclopropyl-1-methyl-1*H*-pyrazol-5-yl)-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-3-(1*H*-indazol-3-yl)-*N*-(5-quinolinyl)-2-propenamide;

(2*E*)-*N*-[3-(acetylamino)phenyl]-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-3-(1*H*-indazol-3-yl)-*N*-(3,4,5-trimethoxyphenyl)-2-propenamide;

(2*E*)-*N*-(3-benzoylphenyl)-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-*N*-[3-chloro-4-(4-morpholinyl)phenyl]-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-*N*-{5-[(diethylamino)sulfonyl]-2-methoxyphenyl}-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-*N*-{4-[2-(diisopropylamino)ethoxy]-3-methoxyphenyl}-3-(1*H*-indazol-3-yl)-2-propenamide;

(2*E*)-3-(1H-indazol-3-yl)-N-(3-methoxy-4-{2-[(2-phenoxyethyl) amino]ethoxy} phenyl)-2-propenamide;

(2*E*)-3-(1H-indazol-3-yl)-N-{3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl}-2-propenamide;

(2*E*)-3-(1H-indazol-3-yl)-N-(3-methoxy-4-{2-[(2-methoxyethyl)amino]-ethoxy}phenyl)-2-propenamide;

(2*E*)-3-(1H-indazol-3-yl)-N-(3-methoxy-4-{2-[methyl(propyl)amino]ethoxy}phenyl)-2-propenamide;

(2*E*)-N-[4-(2-{[2-(4-chlorophenyl)ethyl]amino}ethyoxy)-3-methoxyphenyl]-3-(1H-indazol-3-yl)-2-propenamide;

ethyl 4-{[2-(4-{[(2E)-3-(1H-indazol-3-yl)-2-propenoyl]amino}-2-methoxyphenoxy)
ethyl]amino}-1-piperidine carboxylate;

(2*E*)-N-{4-[2-(4-acetyl-1-piperazinyl)ethoxy]-3-methoxyphenyl}-3-(1H-indazol-3-yl)-2-propenamide;

(2*E*)-*N*-benzyl-3-(1*H*-indazol-3-yl)prop-2-enamide;

(2*E*)-3-(1*H*-indazol-3-yl)-*N*-isobutylprop-2-enamide;

(2*E*)-3-(1*H*-indazol-3-yl)-*N*-(3-morpholin-4-ylpropyl)prop-2-enamide;

(2*E*)-*N*-[2-(4-chlorophenyl)ethyl]-3-(1*H*-indazol-3-yl)prop-2-enamide;

ethyl 1-[(2*E*)-3-(1*H*-indazol-3-yl)prop-2-enoyl]piperidine-4-carboxylate;

3-[(1*E*)-3-(4-benzylpiperidin-1-yl)-3-oxoprop-1-enyl]-1*H*-indazole;

(2*E*)-*N*-ethyl-3-(1*H*-indazol-3-yl)-*N*-(pyridin-4-ylmethyl)prop-2-enamide;

8-[(2*E*)-3-(1*H*-indazol-3-yl)prop-2-enoyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;

3-[(1*E*)-3-oxo-3-(4-pyrazin-2-ylpiperazin-1-yl)prop-1-enyl]-1*H*-indazole;

methyl 4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)benzoate;

4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)benzoic acid;

methyl 3-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)benzoate;

3-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)benzoic acid;

4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-(2-pyridin-3-ylethyl)benzamide;

4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-methyl-N-(2-pyridin-2-ylethyl)benzamide;

4-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide;

3-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-(2-morpholin-4-ylethyl)benzamide;

(2E)-N-(3-((4-benzylpiperazin-1-yl)carbonyl)phenyl)-3-(1H-indazol-3-yl)prop-2-enamide; and

N-ethyl-3-(((2E)-3-(1H-indazol-3-yl)prop-2-enoyl)amino)-N-(pyridin-4-ylmethyl)benzamide

or a salt, solvate, or physiologically functional derivative thereof.

41. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in any one of claims 1 to 40, or a salt,

solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

42. A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate SGK-1 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 40, or a salt, solvate, or a physiologically functional derivative thereof.

43. A compound as claimed in any of claims 1 to 40, or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.

44. Use of a compound as claimed in any of claims 1 to 40, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate SGK-1 activity.